(Q37607078)

21 August 2017

1 reference

title

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis (English)

1 reference

21 August 2017

0 references

0 references

1 reference

Peter C Taylor

1

1 reference

21 August 2017

Marc Feldmann

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Nature Reviews Rheumatology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

578-582

1 reference

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Antibody engineering to develop new antirheumatic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Abandoned therapies and unpublished trials in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

31 March 2020

12 December 2020

TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Fibroblast biology. Signals targeting the synovial fibroblast in arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.181

Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice

31 March 2020

1 reference

12 December 2020

Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.

1 reference

12 December 2020

Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells

1 reference

12 December 2020

Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.181

1 reference

21 August 2017

1 reference